Imaging the Area at Risk in Myocardial Infarction With Cardiovascular Magnetic Resonance

Erik B. Schelbert, MD, MS, FACC; Timothy C. Wong, MD, MS

Myocardial infarction (MI) remains an enormous problem confronting society, representing a leading cause of cardiovascular mortality and a prevalent cause of heart failure. Cardiovascular magnetic resonance (CMR) is emerging as a versatile tool to catalyze our understanding of this entity. At the population level, CMR epidemiology data from the Imaging Cardiac Evaluation to Locate Areas of Necrosis and Detect MI study\(^1\) of older community-dwelling people reveal an enormous burden of MI, demonstrating that most MIs are not detected clinically (Figure), perhaps related to variation in the symptoms that patients may experience.\(^2\) These striking data that used the late gadolinium enhancement (LGE) CMR technique initially described by Kim and colleagues\(^3\) underscore the need for continued vigilance and further investigation into the prevention of MI, the detection of MI, and the specific mechanisms of injury. While the current emphasis on “door to balloon times” with prompt percutaneous intervention to restore myocardial blood flow has decreased short-term mortality to the 2% to 5% range,\(^4\) other relevant outcomes such as in-hospital heart failure\(^5\) and 30-day rehospitalization\(^6\) remain prevalent. Collectively, these observations suggest further opportunities to maximize myocardial salvage, and a need to improve our understanding of how therapies can prevent and/or minimize myocardial damage. Such knowledge may translate into even better outcomes. Investigators require robust tools for these endeavors.

At the preclinical and basic science levels, application of CMR to animal models of disease permit detailed investigations into the pathophysiology of MI. Cine imaging with CMR permits accurate measures of left ventricular mass, volumes, and ejection fraction. With the addition of intravenous gadolinium–based contrast agents that are inherently extracellular for viable cells, LGE identifies irreversibly injured tissue by visualizing the contrast that passively diffuses into (1) necrotic myocytes that cannot maintain their membrane integrity or (2) the replacement fibrosis into which the MI invariably transitions during the chronic phase. Notably, the LGE technique is perhaps the most rigorously validated technique to detect and quantify acute and chronic MI.\(^3,7,8\) In fact, CMR with LGE is the only imaging technique for MI that is validated in an international, multicenter, double-blinded, randomized trial.\(^7\) These CMR techniques render straightforward the quantitation of MI mass relative to global left ventricular mass.

But this parameter of “percent of left ventricular mass that is infarcted” is not the desired metric to measure myocardial salvage needed to test the efficacy of a proposed experimental intervention. For this purpose, the preferred metric is the MI size divided by the denominator of jeopardized myocardium supplied by the culprit coronary artery, which reflects the “area at risk (AAR).” One can therefore define the proportion of myocardial salvage mathematically as 1 – MI/AAR. The area at risk promises greater statistical power and fewer animal experiments to demonstrate efficacy of a proposed intervention. Yet, the AAR is more challenging to measure than myocardial mass because it requires distinguishing unaffected myocardium from injured myocardium that remains viable.

In this issue of JAH\(A\): Journal of the American Heart Association, Grieve et al publish a novel and elegant “whole heart” 3-dimensional method to measure MI size and AAR ex vivo in rodents.\(^9\) Analogous to microspheres, they use iron oxide microparticles to mark perfused myocardium that excludes the AAR. The signal loss from T2* decay introduced by the iron oxide microparticles causes black dots in perfused myocardium evident on CMR gradient echo images. These dots effectively depict the delivery of iron microparticles by

---

The opinions expressed in this article are not necessarily those of the editors or of the American Heart Association.

From the UPMC Heart and Vascular Institute (E.B.S., T.C.W.); UPMC CMR Center (E.B.S., T.C.W.); Department of Medicine, University of Pittsburgh School of Medicine, Pittsburgh, PA (E.B.S., T.C.W.).

Correspondence to: Erik B. Schelbert, MD, MS, FACC, UPMC Heart and Vascular Institute, University of Pittsburgh, 200 Lothrop St, PUH A349, Pittsburgh, PA 15213. E-mail: schelberteb@upmc.edu

J Am Heart Assoc. 2014;3:e001253 doi: 10.1161/JAHA.114.001253.

© 2014 The Authors. Published on behalf of the American Heart Association, Inc., by Wiley Blackwell. This is an open access article under the terms of the Creative Commons Attribution-NonCommercial License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.
perfusion in vivo, whereas the AAR specifically lacks these particles. Within the AAR, gadolinium contrast causes brightening of the infarct itself because gadolinium contrast enters the necrotic myocytes, increasing the local volume of distribution for this contrast agent that is visible on LGE images. Viable cells exclude gadolinium contrast, showing the viable myocardium with the AAR. The video provided by Grieve et al showing progressive cut-away images through the heart in 3 dimensions is impressive and nicely displays their technique.

Their technique provides unambiguous delineation of the AAR that is primarily based on the absence of perfusion, which has advantages over other techniques. While T2 or T1 parametric mapping for myocardial edema—that is, the tissue response to the impaired perfusion—is useful to delineate the AAR for large animals and humans, such parametric mapping is more difficult to translate in rodents with exceedingly high heart rates where fundamentally different pulse sequences are required. Moreover, the AAR that may be apparent initially with in vivo T2 or T1 parametric mapping might be transient and ultimately disappear ex vivo.

Imaging the AAR provides a tool for investigators studying the impact of therapy to alter the course of an evolving MI. For example, the concept of myocardial regeneration with the use of stem cell therapy for the treatment of MI has drawn much attention. However, promising initial studies in animal models of MI have failed to demonstrate convincing efficacy in recent human clinical trials. We note that many of these studies in both animals and humans used myocardial function (regional wall motion or global left ventricular ejection fraction) or infarction size as the primary outcome. As investigators continue to refine stem cell therapy protocols, perhaps the ability to measure infarct size relative to AAR may provide an improved understanding of the effects of these novel therapies. One would expect that the principles outlined in the methodology reported by Grieve et al would extend to large animal models as well.

The iron oxide microparticle AAR technique also introduces several avenues of investigation beyond myocardial salvage therapeutics. For example, one can explore how diffuse myocardial fibrosis influences myocardial salvage strategies. Or, one could further validate the usefulness of changes in myocardial T1 or T2 that has not been universally accepted as a bona fide measure of myocardial edema. Finally, one could also explore the time course of evolving myocardial T1 or T2 changes occurring with variable degrees of ischemia and reperfusion.

The work by Grieve et al builds on the prior advances in imaging MI. By specifically imaging the AAR, which is the preferred denominator for quantifying myocardial salvage, the iron oxide microparticle AAR technique can catalyze investigations into acute MI therapeutics and develop a deeper understanding of its mechanisms of disease.

**Disclosures**

None.

**References**

1. Schelbert EB, Cao JJ, Sigurdsson S, Aspelund T, Kellman P, Aletras AH, Dyke CK, Thorgeirsson G, Einarsdottir G, Launer LJ, Gudnason V, Harris TB, Arai AE. Prevalence and prognosis of unrecognized myocardial infarction determined by cardiac magnetic resonance in older adults. JAMA. 2012;308:890–896.

2. Schelbert EB, Rumsfeld JS, Krumholz HM, Canto JG, Magid DJ, Masoudi FA, Reid KJ, Spertus JA. Ischaemic symptoms, quality of care and mortality during myocardial infarction. Heart. 2008;94:e2.

3. Kim RJ, Fieno DS, Parrish TB, Harris K, Chen EL, Simonetti O, Bundy J, Finn JP, Klocke FJ, Judd RM. Relationship of MRI delayed contrast enhancement to irreversible injury, infarct age, and contractile function. Circulation. 1999;100:1992–2002.

Figure. Fewer than half of all MIs in randomly selected community-dwelling older persons defined by CMR are clinically recognized. The prevalence is displayed according to diabetes status. CMR indicates cardiovascular magnetic resonance; MI, myocardial infarction.
4. Roe MT, Messerger JC, Weintraub WS, Cannon CP, Fonarow GC, Dai D, Chen AY, Klein LW, Masoudi FA, McKay C, Hewitt K, Brindis RG, Peterson ED, Rumsfeld JS. Treatments, trends, and outcomes of acute myocardial infarction and percutaneous coronary intervention. *J Am Coll Cardiol*. 2010;56:254–263.

5. Brieger D, Fox KA, Fitzgerald G, Eagle KA, Budaj A, Avezum A, Granger CB, Costa B, Anderson FA Jr, Steg PG. Predicting freedom from clinical events in non-ST-elevation acute coronary syndromes: the Global Registry of Acute Coronary Events. *Heart*. 2009;95:888–894.

6. Dunlay SM, Weston SA, Killian JM, Bell MR, Jaffe AS, Roger VL. Thirty-day rehospitalizations after acute myocardial infarction: a cohort study. *Ann Intern Med*. 2012;157:11–18.

7. Kim RJ, Albert TS, Wible JH, Elliott MD, Allen JC, Lee JC, Parker M, Napoli A, Judd RM. Performance of delayed-enhancement magnetic resonance imaging with gadoversetamide contrast for the detection and assessment of myocardial infarction: an international, multicenter, double-blinded, randomized trial. *Circulation*. 2008;117:629–637.

8. Schelbert EB, Hsu LY, Anderson SA, Mohanty BD, Karim SM, Kellman P, Aletras AH, Arai AE. Late gadolinium-enhancement cardiac magnetic resonance identifies postinfarction myocardial fibrosis and the border zone at the near cellular level in ex vivo rat heart. *Circ Cardiovasc Imaging*. 2010;3:743–752.

9. Grieve SM, Mazhar J, Callaghan F, Kok CY, Tandy S, Bhindi R, Figtree GA. Automated quantification of myocardial salvage in a rat model of ischemia-reperfusion injury using 3D high-resolution MRI. *J Am Heart Assoc*. 2014;3:e000956. doi: 10.1161/JAHA.114.001105.

10. Ugander M, Bagi PS, Oki AJ, Chen B, Hsu LY, Aletras AH, Shah S, Greiser A, Kellman P, Arai AE. Myocardial edema as detected by pre-contrast T1 and T2 CMR delineates area at risk associated with acute myocardial infarction. *JACC Cardiovasc Imaging*. 2012;5:596–603.

11. Orlic D, Kajstura J, Chimenti S, Jakoniuk I, Anderson SM, Li B, Pickel J, McKay R, Nadal-Ginard B, Bodine DM, Leru A, Anversa P. Bone marrow cells regenerate infarcted myocardium. *Nature*. 2001;410:701–705.

12. Traverse JH, Henry TD, Pepine CJ, Willerson JT, Zhao DX, Ellis SG, Forder JR, Anderson RD, Hatzopoulos AK, Penn MS, Perin EC, Chambers J, Baran KW, Raveendran G, Lambert C, Lerman A, Simon DI, Vaughan DE, Lai D, Gee AP, Taylor DA, Cogle CR, Thomas JD, Olson RE, Bowman S, Francescon J, Geither C, Handberg E, Kappenman C, Westbrook L, Piller LB, Simpson LM, Bariński S, Løghin G, Aguilar D, Richman S, Zierold C, Spoon DB, Bettencourt J, Sayre SL, Vojvodic RW, Skarlatos SI, Gordon DJ, Ebert RF, Kwak M, Moye LA, Simari RD; Cardiovascular Cell Therapy Research N. Effect of the use and timing of bone marrow mononuclear cell delivery on left ventricular function after acute myocardial infarction: the TIME randomized trial. *JAMA*. 2012;308:2380–2389.

13. Surder D, Manka R, Lo Cicero V, Moccetti T, Rufibach K, Soncin S, Turchetto L, Radizzani M, Astori G, Schwitter J, Erme P, Zuber M, Auf der Maur C, Jamshidi P, Gaemperli O, Windecker S, Moschovitis A, Wahl A, Buhler I, Wyss C, Kozek-Friedrich S, Landmesser U, Luscher TF, Corti R. Intracoronary injection of bone marrow-derived mononuclear cells early or late after acute myocardial infarction: effects on global left ventricular function. *Circulation*. 2013;127:1968–1979.

14. Messroghli DR, Nordmeyer S, Dietrich T, Dirsch O, Kaschelt E, Savvatissi O, Oh-I D, Klein C, Berger F, Kuehne T. Assessment of diffuse myocardial fibrosis in rats using small-animal Look-Locker inversion recovery T1 mapping. *Circ Cardiovasc Imaging*. 2011;4:636–640.

15. Arani AE, Leung S, Kellman P. Controversies in cardiovascular MR imaging: reasons why imaging myocardial T2 has clinical and pathophysiologic value in acute myocardial infarction. *Radiology*. 2012;265:23–32.

16. Croisille P, Kim HW, Kim RJ. Controversies in cardiovascular MR imaging: T2-weighted imaging should not be used to delineate the area at risk in ischemic myocardial injury. *Radiology*. 2012;265:12–22.

**Key Words:** Editorials • area at risk • magnetic resonance imaging • myocardial infarction • myocardial salvage